Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

SPHK1 regulates proliferation and survival responses in triple-negative breast cancer

Arpita Datta1, Ser Yue Loo2, Baohua Huang1

  • 1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore.

Oncotarget
|August 26, 2014
PubMed

Insights

Targeting sphingosine kinase 1 (SPHK1) may offer a new strategy against triple-negative breast cancer (TNBC). Inhibiting SPHK1 reduces tumor growth and sensitizes TNBC cells to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
  • TNBC exhibits elevated sphingosine kinase 1 (SPHK1) expression compared to other breast cancers.
  • High SPHK1 levels correlate with poor survival and reduced response to chemotherapy.

Purpose of the Study:

  • To investigate the role of SPHK1 in TNBC.
  • To evaluate SPHK1 inhibition as a therapeutic strategy for TNBC.
  • To assess the combination of SPHK1 inhibition with chemotherapy.

Main Methods:

  • Analysis of SPHK1 gene expression in TNBC.
  • Inhibition of SPHK1 using siRNA and a specific inhibitor (SKI-5C).
  • Assessment of cell growth, signaling pathways (ERK1/2, AKT), and chemosensitization in vitro and in vivo (xenograft model).

Main Results:

  • SPHK1 inhibition reduced TNBC cell growth in vitro and in vivo.
  • SPHK1 inhibition attenuated ERK1/2 and AKT signaling pathways.
  • SPHK1 inhibition sensitized TNBC cells to chemotherapeutic drugs.

Conclusions:

  • SPHK1 is a potential therapeutic target for TNBC.
  • Inhibiting SPHK1 counteracts oncogenic signaling pathways crucial for TNBC growth.
  • Combination therapy with SPHK1 inhibitors and chemotherapy may be effective against TNBC.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

12.8K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K